Phosphodiesterase inhibitors say NO to Alzheimer's disease

Seyed Mohammad Nabavi, Sylwia Talarek, Joanna Listos, Seyed Fazel Nabavi, Kasi Pandima Devi, Marcos Roberto de Oliveira, Devesh Tewari, Sandro Argüelles, Saeed Mehrzadi, Azam Hosseinzadeh, Grazia D'onofrio, Ilkay Erdogan Orhan, Antoni Sureda, Suowen Xu, Saeedeh Momtaz, Mohammad Hosein Farzaei

Research output: Contribution to journalReview article

Abstract

Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions. PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive neurodegenerative disorder which affect mostly senile people in the world and only symptomatic treatment particularly using cholinesterase inhibitors in clinic is available at the moment for AD. Consequently, novel treatment strategies towards AD are still searched extensively. Since PDEs are broadly expressed in the brain, PDEIs are considered to modulate neurodegenerative conditions through regulating cAMP and cGMP in the brain. In this sense, several synthetic or natural molecules inhibiting various PDE subtypes such as rolipram and roflumilast (PDE4 inhibitors), vinpocetine (PDE1 inhibitor), cilostazol and milrinone (PDE3 inhibitors), sildenafil and tadalafil (PDE5 inhibitors), etc have been reported showing encouraging results for the treatment of AD. In this review, PDE superfamily will be scrutinized from the view point of structural features, isoforms, functions and pharmacology particularly attributed to PDEs as target for AD therapy.

Original languageEnglish
Article number110822
JournalFood and Chemical Toxicology
Volume134
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

Phosphodiesterase Inhibitors
Alzheimer disease
Phosphoric Diester Hydrolases
Alzheimer Disease
guanosine monophosphate
cyclic AMP
vinpocetine
Protein Isoforms
Phosphodiesterase 3 Inhibitors
cholinesterase inhibitors
Phosphodiesterase 4 Inhibitors
Milrinone
Rolipram
brain
Phosphodiesterase 5 Inhibitors
Brain
therapeutics
autoimmune diseases
second messengers
Cholinesterase Inhibitors

Keywords

  • Alzheimer's disease
  • cAMP
  • cGMP
  • Isoform
  • Phosphodiesterase
  • Subtype

ASJC Scopus subject areas

  • Food Science
  • Toxicology

Cite this

Nabavi, S. M., Talarek, S., Listos, J., Nabavi, S. F., Devi, K. P., Roberto de Oliveira, M., ... Farzaei, M. H. (2019). Phosphodiesterase inhibitors say NO to Alzheimer's disease. Food and Chemical Toxicology, 134, [110822]. https://doi.org/10.1016/j.fct.2019.110822

Phosphodiesterase inhibitors say NO to Alzheimer's disease. / Nabavi, Seyed Mohammad; Talarek, Sylwia; Listos, Joanna; Nabavi, Seyed Fazel; Devi, Kasi Pandima; Roberto de Oliveira, Marcos; Tewari, Devesh; Argüelles, Sandro; Mehrzadi, Saeed; Hosseinzadeh, Azam; D'onofrio, Grazia; Orhan, Ilkay Erdogan; Sureda, Antoni; Xu, Suowen; Momtaz, Saeedeh; Farzaei, Mohammad Hosein.

In: Food and Chemical Toxicology, Vol. 134, 110822, 01.12.2019.

Research output: Contribution to journalReview article

Nabavi, SM, Talarek, S, Listos, J, Nabavi, SF, Devi, KP, Roberto de Oliveira, M, Tewari, D, Argüelles, S, Mehrzadi, S, Hosseinzadeh, A, D'onofrio, G, Orhan, IE, Sureda, A, Xu, S, Momtaz, S & Farzaei, MH 2019, 'Phosphodiesterase inhibitors say NO to Alzheimer's disease', Food and Chemical Toxicology, vol. 134, 110822. https://doi.org/10.1016/j.fct.2019.110822
Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M et al. Phosphodiesterase inhibitors say NO to Alzheimer's disease. Food and Chemical Toxicology. 2019 Dec 1;134. 110822. https://doi.org/10.1016/j.fct.2019.110822
Nabavi, Seyed Mohammad ; Talarek, Sylwia ; Listos, Joanna ; Nabavi, Seyed Fazel ; Devi, Kasi Pandima ; Roberto de Oliveira, Marcos ; Tewari, Devesh ; Argüelles, Sandro ; Mehrzadi, Saeed ; Hosseinzadeh, Azam ; D'onofrio, Grazia ; Orhan, Ilkay Erdogan ; Sureda, Antoni ; Xu, Suowen ; Momtaz, Saeedeh ; Farzaei, Mohammad Hosein. / Phosphodiesterase inhibitors say NO to Alzheimer's disease. In: Food and Chemical Toxicology. 2019 ; Vol. 134.
@article{51a0b50a73ba43359f16cf13119ec68e,
title = "Phosphodiesterase inhibitors say NO to Alzheimer's disease",
abstract = "Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions. PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive neurodegenerative disorder which affect mostly senile people in the world and only symptomatic treatment particularly using cholinesterase inhibitors in clinic is available at the moment for AD. Consequently, novel treatment strategies towards AD are still searched extensively. Since PDEs are broadly expressed in the brain, PDEIs are considered to modulate neurodegenerative conditions through regulating cAMP and cGMP in the brain. In this sense, several synthetic or natural molecules inhibiting various PDE subtypes such as rolipram and roflumilast (PDE4 inhibitors), vinpocetine (PDE1 inhibitor), cilostazol and milrinone (PDE3 inhibitors), sildenafil and tadalafil (PDE5 inhibitors), etc have been reported showing encouraging results for the treatment of AD. In this review, PDE superfamily will be scrutinized from the view point of structural features, isoforms, functions and pharmacology particularly attributed to PDEs as target for AD therapy.",
keywords = "Alzheimer's disease, cAMP, cGMP, Isoform, Phosphodiesterase, Subtype",
author = "Nabavi, {Seyed Mohammad} and Sylwia Talarek and Joanna Listos and Nabavi, {Seyed Fazel} and Devi, {Kasi Pandima} and {Roberto de Oliveira}, Marcos and Devesh Tewari and Sandro Arg{\"u}elles and Saeed Mehrzadi and Azam Hosseinzadeh and Grazia D'onofrio and Orhan, {Ilkay Erdogan} and Antoni Sureda and Suowen Xu and Saeedeh Momtaz and Farzaei, {Mohammad Hosein}",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.fct.2019.110822",
language = "English",
volume = "134",
journal = "Food and Chemical Toxicology",
issn = "0278-6915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Phosphodiesterase inhibitors say NO to Alzheimer's disease

AU - Nabavi, Seyed Mohammad

AU - Talarek, Sylwia

AU - Listos, Joanna

AU - Nabavi, Seyed Fazel

AU - Devi, Kasi Pandima

AU - Roberto de Oliveira, Marcos

AU - Tewari, Devesh

AU - Argüelles, Sandro

AU - Mehrzadi, Saeed

AU - Hosseinzadeh, Azam

AU - D'onofrio, Grazia

AU - Orhan, Ilkay Erdogan

AU - Sureda, Antoni

AU - Xu, Suowen

AU - Momtaz, Saeedeh

AU - Farzaei, Mohammad Hosein

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions. PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive neurodegenerative disorder which affect mostly senile people in the world and only symptomatic treatment particularly using cholinesterase inhibitors in clinic is available at the moment for AD. Consequently, novel treatment strategies towards AD are still searched extensively. Since PDEs are broadly expressed in the brain, PDEIs are considered to modulate neurodegenerative conditions through regulating cAMP and cGMP in the brain. In this sense, several synthetic or natural molecules inhibiting various PDE subtypes such as rolipram and roflumilast (PDE4 inhibitors), vinpocetine (PDE1 inhibitor), cilostazol and milrinone (PDE3 inhibitors), sildenafil and tadalafil (PDE5 inhibitors), etc have been reported showing encouraging results for the treatment of AD. In this review, PDE superfamily will be scrutinized from the view point of structural features, isoforms, functions and pharmacology particularly attributed to PDEs as target for AD therapy.

AB - Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions. PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive neurodegenerative disorder which affect mostly senile people in the world and only symptomatic treatment particularly using cholinesterase inhibitors in clinic is available at the moment for AD. Consequently, novel treatment strategies towards AD are still searched extensively. Since PDEs are broadly expressed in the brain, PDEIs are considered to modulate neurodegenerative conditions through regulating cAMP and cGMP in the brain. In this sense, several synthetic or natural molecules inhibiting various PDE subtypes such as rolipram and roflumilast (PDE4 inhibitors), vinpocetine (PDE1 inhibitor), cilostazol and milrinone (PDE3 inhibitors), sildenafil and tadalafil (PDE5 inhibitors), etc have been reported showing encouraging results for the treatment of AD. In this review, PDE superfamily will be scrutinized from the view point of structural features, isoforms, functions and pharmacology particularly attributed to PDEs as target for AD therapy.

KW - Alzheimer's disease

KW - cAMP

KW - cGMP

KW - Isoform

KW - Phosphodiesterase

KW - Subtype

UR - http://www.scopus.com/inward/record.url?scp=85072265292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072265292&partnerID=8YFLogxK

U2 - 10.1016/j.fct.2019.110822

DO - 10.1016/j.fct.2019.110822

M3 - Review article

AN - SCOPUS:85072265292

VL - 134

JO - Food and Chemical Toxicology

JF - Food and Chemical Toxicology

SN - 0278-6915

M1 - 110822

ER -